LENZ Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Del Mar, California and currently employs 6 full-time employees. The company went IPO on 2021-06-25. LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The firm is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.

LENZ Dividends

LENZ dividend metrics

Dividend per share

LENZ dividend history